Amid Rahi

Dr. Amid Rahi


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Environmental Research
Verified
Journal Article
Closed access
EPEsmail Pishbin
Esmail Pishbin
FSFatemeh Sadri
Fatemeh Sadri
ADAmin Dehghan
Amin Dehghan
MKMohammad javad Kiani
Mohammad javad Kiani
NHNader Hashemi
Nader Hashemi
ARAmid Rahi
Amid Rahi

11 July 2024 in Nanotechnology
Verified
Journal Article
Open access
PDF file
SSSohrab Sardari
Sohrab Sardari
AHAli Hheidari
Ali Hheidari
MGMaryam Ghodousi
Maryam Ghodousi
ARAmid Rahi
Amid Rahi
EPEsmail Pishbin
Esmail Pishbin
Tissue engineering is a multidisciplinary field that merges engineering, material science, and medical biology in order to develop biological alternatives for repairing, replacing, maintaining, or boosting the functionality of tissues and organs. The ultimate goal of tissue engineering is to create biological alternatives for repairing, replacing, maintaining, or enhancing the functionality of tissues and organs. However, the current landscape of tissue engineering techniques presents several challenges, including a lack of suitable biomaterials, inadequate cell proliferation, limited methodologies for replicating desired physiological structures, and the unstable and insufficient production of growth factors, which are essential for facilitating cell communication and the appropriate cellular responses. Despite these challenges, there has been significant progress made in tissue engineering techniques in recent years. Nanoparticles hold a major role within the realm of nanotechnology due to their unique qualities that change with size. These particles, which provide potential solutions to the issues that are met in tissue engineering, have helped propel nanotechnology to its current state of prominence. Despite substantial breakthroughs in the utilization of nanoparticles over the past two decades, the full range of their potential in addressing the difficulties within tissue engineering remains largely untapped. This is due to the fact that these advancements have occurred in relatively isolated pockets. In the realm of tissue engineering, the purpose of this research is to conduct an in-depth investigation of the several ways in which various types of nanoparticles might be put to use. In addition to this, it sheds light on the challenges that need to be conquered in order to unlock the maximum potential of nanotechnology in this area.

9 December 2024 in BioNanoScience
Verified
Journal Article
Closed access
PDF file
RDRasool Dezhkam
Rasool Dezhkam
EPEsmail Pishbin
Esmail Pishbin
EMErmia Azari Moghaddam
Ermia Azari Moghaddam
ARAmid Rahi
Amid Rahi
NHNader Hashemi
Nader Hashemi
ASAmir Shamloo
Amir Shamloo

5 March 2026 in Results in Engineering
Verified
Journal Article
Open access
ADAmin Dehghan
Amin Dehghan
BJBahareh Mohammadi Jobani
Bahareh Mohammadi Jobani
RMRamtin Malekpour
Ramtin Malekpour
MKMohammad Javad Kiani
Mohammad Javad Kiani
MEManouchehr Eghbal
Manouchehr Eghbal
ARAmid Rahi
Amid Rahi

9 November 2026 in Scientific Reviews
Verified
Journal Article
Open access
BJBahareh Mohammadi Jobani
Bahareh Mohammadi Jobani
EPEsmail Pishbin
Esmail Pishbin
ADAmin Dehghan
Amin Dehghan
SSSiamak Salami
Siamak Salami
ARAmid Rahi
Amid Rahi
ZSZahra Shahsavari
Zahra Shahsavari

15 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MKM. Karimi
M. Karimi
NSNaghmeh Sattarahmady
Naghmeh Sattarahmady
SFS. Fahim
S. Fahim
ABA. Barazesh
A. Barazesh
RVR. Dehdari Vais
R. Dehdari Vais
HHHossein Heli
Hossein Heli
Leishmania major causes cutaneous leishmaniasis with the primary challenges in treatment include the emergence of resistance, prolonged treatment duration, high costs associated with current medications and their toxicity. Additionally, the intracellular nature of the parasite hinders drug access, as the drug needs to cross the host cell membrane and the phagolysosome, making its effect more difficult. While the therapeutic effects of fluconazole on leishmaniasis have been explored in several studies, its low bioavailability and solubility should be circumvented by new and targeted carriers without these issues. In this study, fluconazole was encapsulated within mannosylated-albumin nanoparticles (NPs) for selective delivery to the host macrophages for the treatment of Leishmania major. Both targeted and non-targeted carriers were synthesized and characterized by measurements on zeta (z) potential, particle size, mannosylation level, fluconazole entrapment efficiency and loading capacity, uptake level by the macrophages, and fluconazole release rate. In vitro cytotoxicity against macrophages, promastigotes and amastigotes was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and the results were compared with free fluconazole and glucantime (meglumine antimoniate). IC50 for glucantime, fluconazole, fluconazole-albumin NPs, and targeted fluconazole-albumin NPs against the Leishmania major promastigotes after 48 hours were obtained as 180.3 ± 8.8, 134.7 ± 9.1, 105.6 ± 11.1, and 62.2 ± 10.4 μg mL-1, respectively. Treatment of Leishmania major amastigotes using glucantime, fluconazole, fluconazole-albumin NPs, and targeted fluconazole-albumin NPs had IC50 of 122.9 ± 11.3, 101.2 ± 9.5, 71.6 ± 5.1, and 28.0 ± 3.3 μg mL-1, respectively. In addition, targeted fluconazole-albumin NPs represented high values of selectivity toward the parasite promastigotes as well as amastigotes, compared to the host cells.